11th JUNE 2021 – YTB Healthcare Sdn Bhd, a subsidiary of Yong Tai Bhd has today received the first batch of inactivated Covid-19 Vaccine.

The Vaccine was developed by the Group’s strategic partner, Shenzhen Kangtai Biological Products Co., Ltd. (“SZKT”).

The arrival of the Vaccine, which was witnessed by Y.B. Senator Jaziri Alkaf Abdillah Suffian and YTB’s Chief Executive Officer and Executive Director Datuk Wira Boo Kuang Loon.

SZKT’s Vaccine has obtained the Emergency Use Authorisation (“EUA”) granted by the Government of China. SZKT has also commenced its vaccination programme in China, and has been used to vaccinate millions of China citizens since 1 June 2021.

This Phase 3 clinical trial will enrol 3,000 subjects from Malaysia, and the subjects will receive the Vaccine in 2 doses 28 days apart.

Yong Tai is the exclusive distributor for SZKT’s Vaccine with a period of 5 years (renewable) for no less than 20 million doses yearly. “This venture will create a strong income stream and contribute positively to the Group,” Datuk Wira Boo said.

0.615 targeted